(RTTNews) - Sonnet BioTherapeutics Holdings, Inc. (SONN), an oncology-focused biotechnology company, on Tuesday announced an expansion of its Phase 1 SB101 clinical study of SON-1010 or IL12-FHAB to evaluate the combination of SON-1010 with trabectedin Yondelis in patients with advanced soft-tissue sarcomas or STS.
This decision comes after promising monotherapy results of SON-1010 in patients with advanced solid tumors.
The new cohort of the trial will assess the immune-oncology effects of SON-1010 in combination with trabectedin, a chemotherapeutic approved for certain STS.
This combination aims to enhance the immune response in the tumor microenvironment, potentially improving treatment outcomes for patients with liposarcoma and leiomyosarcoma.
Enrollment for this cohort is currently underway, and topline safety data is expected by the second half of 2025.
The Phase 1 trial will examine the safety, tolerability, and pharmacokinetics of the combination at the maximum tolerated dose or MTD of 1200 ng/kg of SON-1010.
This expansion could position SON-1010 for a future Phase 2 study and potentially improve treatment options for STS patients.
SON-1010 is a recombinant human interleukin-12 or rhIL-12 engineered with Sonnet's Fully Human Albumin Binding or FHAB platform, designed to target tumors and enhance immune responses.
Currently, SONN is trading at $1.47 down by 4.55%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
